中文名稱:Clofarabine | 英文名稱:Clofarabine |
CAS:123318-82-1 | 品牌: 一研 |
保存條件: Store at -20°C | 產(chǎn)品類別: 抑制劑 |
Cas : 123318-82-1 |
產(chǎn)品屬性:
產(chǎn)品名稱 | 規(guī)格 | CAS號(hào) | 型號(hào) |
Clofarabine | 10mM (in 1mL DMSO) 5mg 25mg 100mg | 123318-82-1 | EY-Y0165525 |
Cas No.123318-82-1
別名
化學(xué)名 (2R,3R,4S,5R)-5-(6-amino-2-chloropurin-9-yl)-4-fluoro-2-(hydroxymethyl)oxolan-3-ol
分子式 C10H11ClFN5O3
分子量 303.68
溶解度 ≥ 15.184mg/mL in DMSO
儲(chǔ)存條件 Store at -20°C
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.
Shipping Condition Evaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
產(chǎn)品描述:
DCK is a key cytosolic enzyme in the DNA-synthesis salvage pathway and is responsible for the phosphorylation of clofarabine.
Clofarabine is phosphorylated to form clofarabine triphosphate, which competes with dATP for DNA polymerase-α and -ε. At the same time, clofarabine-monophosphate is incorporated into internal and terminal DNA sites, which impaired DNA elongation and repair. Clofarabine triphosphate inhibits ribonucleotide reductase with IC50 value of 65 nM, which then reduced dCTP and dATP. Clofarabine is efficiently transported into cells through nucleoside transporters hENT1, hENT2, and hCNT2. Clofarabine results in release of cytochrome c, apoptosis protease-activating factor 1 (APAF1), apoptotic-inducing factor (AIF) and caspase 9 into the cytosol. In both rapidly growing and quiescent tumours, clofarabine has anticancer activity because of its inhibition of DNA synthesis and induction of apoptosis.
Implanted human tumour xenografts in athymic nude or severe combined immune deficiency mice, Clofarabine administered intraperitoneally had significant antitumor activity.
References:
[1]. Bonate PL, Arthaud L, Cantrell WR Jr, et al. Discovery and development of clofarabine: a nucleoside analogue for treating cancer. Nat Rev Drug Discov, 2006, 5(10): 855-863.
成立日期 | 2014-06-05 (11年) | 注冊(cè)資本 | 100 |
員工人數(shù) | 50-100人 | 年?duì)I業(yè)額 | ¥ 100萬以內(nèi) |
主營(yíng)行業(yè) | 生化試劑,抗體,細(xì)胞培養(yǎng),分子生物學(xué),免疫安全 | 經(jīng)營(yíng)模式 | 工廠,試劑 |
產(chǎn)品名稱 | 價(jià)格 | 公司名稱 | 報(bào)價(jià)日期 | |
---|---|---|---|---|
詢價(jià) |
VIP3年
|
湖北魏氏化學(xué)試劑股份有限公司
|
2024-11-01 | |
詢價(jià) |
VIP5年
|
上海澤葉生物科技有限公司
|
2024-11-01 | |
¥362.90 |
VIP13年
|
上海阿拉丁生化科技股份有限公司
|
2024-10-31 | |
詢價(jià) |
VIP6年
|
成都彼樣生物科技有限公司
|
2024-10-29 | |
詢價(jià) |
VIP12年
|
上海灝云化工科技有限公司
|
2024-10-16 | |
詢價(jià) |
南京百鑫德諾生物科技有限公司
|
2024-09-26 | ||
¥127 |
VIP12年
|
上海陶術(shù)生物科技有限公司
|
2024-09-14 | |
詢價(jià) |
VIP4年
|
陜西締都醫(yī)藥化工有限公司
|
2024-09-12 | |
詢價(jià) |
武漢貝樂葉生物醫(yī)藥科技有限公司
|
2024-08-31 | ||
¥402.90 |
VIP1年
|
上海阿拉丁生化科技股份有限公司
|
2024-08-16 |